nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—CYP2D6—breast cancer	0.194	1	CbGaD
Tapentadol—UGT1A9—Irinotecan—breast cancer	0.0708	0.172	CbGbCtD
Tapentadol—UGT2B7—Epirubicin—breast cancer	0.0689	0.167	CbGbCtD
Tapentadol—CYP2C9—Anastrozole—breast cancer	0.0461	0.112	CbGbCtD
Tapentadol—CYP2C19—Lapatinib—breast cancer	0.037	0.09	CbGbCtD
Tapentadol—CYP2C9—Idarubicin—breast cancer	0.035	0.085	CbGbCtD
Tapentadol—CYP2D6—Idarubicin—breast cancer	0.032	0.0777	CbGbCtD
Tapentadol—CYP2C9—Capecitabine—breast cancer	0.0192	0.0466	CbGbCtD
Tapentadol—CYP2C19—Tamoxifen—breast cancer	0.0185	0.0451	CbGbCtD
Tapentadol—CYP2D6—Vinorelbine—breast cancer	0.0156	0.0379	CbGbCtD
Tapentadol—CYP2C9—Tamoxifen—breast cancer	0.0154	0.0375	CbGbCtD
Tapentadol—CYP2D6—Tamoxifen—breast cancer	0.0141	0.0343	CbGbCtD
Tapentadol—CYP2C9—Paclitaxel—breast cancer	0.012	0.0292	CbGbCtD
Tapentadol—CYP2C9—Fluorouracil—breast cancer	0.0114	0.0276	CbGbCtD
Tapentadol—CYP2D6—Vinblastine—breast cancer	0.00962	0.0234	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—breast cancer	0.00591	0.0144	CbGbCtD
Tapentadol—Edrophonium—ACHE—breast cancer	0.00184	0.276	CrCbGaD
Tapentadol—Rivastigmine—ACHE—breast cancer	0.00171	0.257	CrCbGaD
Tapentadol—Edrophonium—BCHE—breast cancer	0.00108	0.162	CrCbGaD
Tapentadol—Rivastigmine—BCHE—breast cancer	0.00101	0.151	CrCbGaD
Tapentadol—Rivastigmine—CYP2D6—breast cancer	0.000553	0.0828	CrCbGaD
Tapentadol—Rivastigmine—CYP3A4—breast cancer	0.000475	0.0711	CrCbGaD
Tapentadol—Skin disorder—Docetaxel—breast cancer	8.24e-05	0.000335	CcSEcCtD
Tapentadol—Oedema—Capecitabine—breast cancer	8.21e-05	0.000334	CcSEcCtD
Tapentadol—Bradycardia—Epirubicin—breast cancer	8.2e-05	0.000334	CcSEcCtD
Tapentadol—Diarrhoea—Gemcitabine—breast cancer	8.18e-05	0.000333	CcSEcCtD
Tapentadol—Infection—Capecitabine—breast cancer	8.16e-05	0.000332	CcSEcCtD
Tapentadol—Dizziness—Irinotecan—breast cancer	8.11e-05	0.00033	CcSEcCtD
Tapentadol—Shock—Capecitabine—breast cancer	8.08e-05	0.000329	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—breast cancer	8.07e-05	0.000328	CcSEcCtD
Tapentadol—Nervous system disorder—Capecitabine—breast cancer	8.05e-05	0.000328	CcSEcCtD
Tapentadol—Eye disorder—Methotrexate—breast cancer	8.04e-05	0.000327	CcSEcCtD
Tapentadol—Diarrhoea—Fluorouracil—breast cancer	8.04e-05	0.000327	CcSEcCtD
Tapentadol—Tachycardia—Capecitabine—breast cancer	8.01e-05	0.000326	CcSEcCtD
Tapentadol—Hypoaesthesia—Epirubicin—breast cancer	8.01e-05	0.000326	CcSEcCtD
Tapentadol—Cardiac disorder—Methotrexate—breast cancer	7.98e-05	0.000325	CcSEcCtD
Tapentadol—Skin disorder—Capecitabine—breast cancer	7.98e-05	0.000325	CcSEcCtD
Tapentadol—Urinary tract disorder—Epirubicin—breast cancer	7.95e-05	0.000324	CcSEcCtD
Tapentadol—Urticaria—Paclitaxel—breast cancer	7.95e-05	0.000323	CcSEcCtD
Tapentadol—Hyperhidrosis—Capecitabine—breast cancer	7.94e-05	0.000323	CcSEcCtD
Tapentadol—Hypotension—Docetaxel—breast cancer	7.92e-05	0.000323	CcSEcCtD
Tapentadol—Connective tissue disorder—Epirubicin—breast cancer	7.91e-05	0.000322	CcSEcCtD
Tapentadol—Urethral disorder—Epirubicin—breast cancer	7.89e-05	0.000321	CcSEcCtD
Tapentadol—Angiopathy—Methotrexate—breast cancer	7.81e-05	0.000318	CcSEcCtD
Tapentadol—Vomiting—Irinotecan—breast cancer	7.8e-05	0.000317	CcSEcCtD
Tapentadol—Vomiting—Mitoxantrone—breast cancer	7.8e-05	0.000317	CcSEcCtD
Tapentadol—Immune system disorder—Methotrexate—breast cancer	7.77e-05	0.000316	CcSEcCtD
Tapentadol—Dizziness—Fluorouracil—breast cancer	7.77e-05	0.000316	CcSEcCtD
Tapentadol—Visual impairment—Epirubicin—breast cancer	7.76e-05	0.000316	CcSEcCtD
Tapentadol—Mediastinal disorder—Methotrexate—breast cancer	7.75e-05	0.000316	CcSEcCtD
Tapentadol—Rash—Mitoxantrone—breast cancer	7.74e-05	0.000315	CcSEcCtD
Tapentadol—Rash—Irinotecan—breast cancer	7.74e-05	0.000315	CcSEcCtD
Tapentadol—Dermatitis—Irinotecan—breast cancer	7.73e-05	0.000315	CcSEcCtD
Tapentadol—Dermatitis—Mitoxantrone—breast cancer	7.73e-05	0.000315	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Docetaxel—breast cancer	7.73e-05	0.000314	CcSEcCtD
Tapentadol—Chills—Methotrexate—breast cancer	7.72e-05	0.000314	CcSEcCtD
Tapentadol—Headache—Mitoxantrone—breast cancer	7.69e-05	0.000313	CcSEcCtD
Tapentadol—Headache—Irinotecan—breast cancer	7.69e-05	0.000313	CcSEcCtD
Tapentadol—Hypotension—Capecitabine—breast cancer	7.67e-05	0.000312	CcSEcCtD
Tapentadol—Insomnia—Docetaxel—breast cancer	7.67e-05	0.000312	CcSEcCtD
Tapentadol—Paraesthesia—Docetaxel—breast cancer	7.61e-05	0.00031	CcSEcCtD
Tapentadol—Vomiting—Gemcitabine—breast cancer	7.6e-05	0.000309	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—breast cancer	7.58e-05	0.000309	CcSEcCtD
Tapentadol—Dyspnoea—Docetaxel—breast cancer	7.56e-05	0.000308	CcSEcCtD
Tapentadol—Somnolence—Docetaxel—breast cancer	7.54e-05	0.000307	CcSEcCtD
Tapentadol—Mental disorder—Methotrexate—breast cancer	7.54e-05	0.000307	CcSEcCtD
Tapentadol—Rash—Gemcitabine—breast cancer	7.53e-05	0.000307	CcSEcCtD
Tapentadol—Dermatitis—Gemcitabine—breast cancer	7.53e-05	0.000306	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—breast cancer	7.52e-05	0.000306	CcSEcCtD
Tapentadol—Malnutrition—Methotrexate—breast cancer	7.49e-05	0.000305	CcSEcCtD
Tapentadol—Headache—Gemcitabine—breast cancer	7.49e-05	0.000305	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Capecitabine—breast cancer	7.48e-05	0.000304	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—breast cancer	7.47e-05	0.000304	CcSEcCtD
Tapentadol—Vomiting—Fluorouracil—breast cancer	7.47e-05	0.000304	CcSEcCtD
Tapentadol—Dyspepsia—Docetaxel—breast cancer	7.46e-05	0.000304	CcSEcCtD
Tapentadol—Insomnia—Capecitabine—breast cancer	7.43e-05	0.000302	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—breast cancer	7.41e-05	0.000302	CcSEcCtD
Tapentadol—Rash—Fluorouracil—breast cancer	7.41e-05	0.000302	CcSEcCtD
Tapentadol—Dermatitis—Fluorouracil—breast cancer	7.4e-05	0.000301	CcSEcCtD
Tapentadol—Paraesthesia—Capecitabine—breast cancer	7.37e-05	0.0003	CcSEcCtD
Tapentadol—Decreased appetite—Docetaxel—breast cancer	7.37e-05	0.0003	CcSEcCtD
Tapentadol—Hypersensitivity—Paclitaxel—breast cancer	7.37e-05	0.0003	CcSEcCtD
Tapentadol—Headache—Fluorouracil—breast cancer	7.36e-05	0.0003	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—breast cancer	7.36e-05	0.000299	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Docetaxel—breast cancer	7.32e-05	0.000298	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—breast cancer	7.32e-05	0.000298	CcSEcCtD
Tapentadol—Dyspnoea—Capecitabine—breast cancer	7.32e-05	0.000298	CcSEcCtD
Tapentadol—Fatigue—Docetaxel—breast cancer	7.31e-05	0.000298	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—breast cancer	7.3e-05	0.000297	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—breast cancer	7.3e-05	0.000297	CcSEcCtD
Tapentadol—Nausea—Irinotecan—breast cancer	7.29e-05	0.000297	CcSEcCtD
Tapentadol—Nausea—Mitoxantrone—breast cancer	7.29e-05	0.000297	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—breast cancer	7.27e-05	0.000296	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—breast cancer	7.26e-05	0.000295	CcSEcCtD
Tapentadol—Constipation—Docetaxel—breast cancer	7.25e-05	0.000295	CcSEcCtD
Tapentadol—Dyspepsia—Capecitabine—breast cancer	7.23e-05	0.000294	CcSEcCtD
Tapentadol—Chills—Epirubicin—breast cancer	7.22e-05	0.000294	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—breast cancer	7.18e-05	0.000292	CcSEcCtD
Tapentadol—Asthenia—Paclitaxel—breast cancer	7.18e-05	0.000292	CcSEcCtD
Tapentadol—Decreased appetite—Capecitabine—breast cancer	7.14e-05	0.00029	CcSEcCtD
Tapentadol—Nausea—Gemcitabine—breast cancer	7.1e-05	0.000289	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Capecitabine—breast cancer	7.09e-05	0.000288	CcSEcCtD
Tapentadol—Fatigue—Capecitabine—breast cancer	7.08e-05	0.000288	CcSEcCtD
Tapentadol—Pruritus—Paclitaxel—breast cancer	7.08e-05	0.000288	CcSEcCtD
Tapentadol—Vision blurred—Methotrexate—breast cancer	7.06e-05	0.000287	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—breast cancer	7.05e-05	0.000287	CcSEcCtD
Tapentadol—Constipation—Capecitabine—breast cancer	7.02e-05	0.000286	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—breast cancer	7.01e-05	0.000285	CcSEcCtD
Tapentadol—Feeling abnormal—Docetaxel—breast cancer	6.99e-05	0.000284	CcSEcCtD
Tapentadol—Nausea—Fluorouracil—breast cancer	6.98e-05	0.000284	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—breast cancer	6.96e-05	0.000283	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—breast cancer	6.91e-05	0.000281	CcSEcCtD
Tapentadol—Tension—Epirubicin—breast cancer	6.88e-05	0.00028	CcSEcCtD
Tapentadol—Diarrhoea—Paclitaxel—breast cancer	6.85e-05	0.000279	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—breast cancer	6.81e-05	0.000277	CcSEcCtD
Tapentadol—Feeling abnormal—Capecitabine—breast cancer	6.77e-05	0.000275	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—breast cancer	6.76e-05	0.000275	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—breast cancer	6.73e-05	0.000274	CcSEcCtD
Tapentadol—Vertigo—Methotrexate—breast cancer	6.73e-05	0.000274	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—breast cancer	6.71e-05	0.000273	CcSEcCtD
Tapentadol—Chills—Doxorubicin—breast cancer	6.68e-05	0.000272	CcSEcCtD
Tapentadol—Dizziness—Paclitaxel—breast cancer	6.62e-05	0.000269	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—breast cancer	6.61e-05	0.000269	CcSEcCtD
Tapentadol—Cough—Methotrexate—breast cancer	6.54e-05	0.000266	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—breast cancer	6.53e-05	0.000266	CcSEcCtD
Tapentadol—Urticaria—Capecitabine—breast cancer	6.52e-05	0.000265	CcSEcCtD
Tapentadol—Convulsion—Methotrexate—breast cancer	6.49e-05	0.000264	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—breast cancer	6.48e-05	0.000264	CcSEcCtD
Tapentadol—Agitation—Epirubicin—breast cancer	6.44e-05	0.000262	CcSEcCtD
Tapentadol—Arthralgia—Methotrexate—breast cancer	6.38e-05	0.000259	CcSEcCtD
Tapentadol—Tension—Doxorubicin—breast cancer	6.36e-05	0.000259	CcSEcCtD
Tapentadol—Vomiting—Paclitaxel—breast cancer	6.36e-05	0.000259	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	6.33e-05	0.000258	CcSEcCtD
Tapentadol—Rash—Paclitaxel—breast cancer	6.31e-05	0.000257	CcSEcCtD
Tapentadol—Dermatitis—Paclitaxel—breast cancer	6.3e-05	0.000257	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—breast cancer	6.3e-05	0.000256	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—breast cancer	6.3e-05	0.000256	CcSEcCtD
Tapentadol—Syncope—Epirubicin—breast cancer	6.29e-05	0.000256	CcSEcCtD
Tapentadol—Headache—Paclitaxel—breast cancer	6.27e-05	0.000255	CcSEcCtD
Tapentadol—Hypersensitivity—Docetaxel—breast cancer	6.25e-05	0.000254	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—breast cancer	6.19e-05	0.000252	CcSEcCtD
Tapentadol—Confusional state—Methotrexate—breast cancer	6.16e-05	0.000251	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—breast cancer	6.16e-05	0.000251	CcSEcCtD
Tapentadol—Cough—Epirubicin—breast cancer	6.12e-05	0.000249	CcSEcCtD
Tapentadol—Anaphylactic shock—Methotrexate—breast cancer	6.11e-05	0.000249	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—breast cancer	6.11e-05	0.000249	CcSEcCtD
Tapentadol—Asthenia—Docetaxel—breast cancer	6.08e-05	0.000248	CcSEcCtD
Tapentadol—Convulsion—Epirubicin—breast cancer	6.07e-05	0.000247	CcSEcCtD
Tapentadol—Infection—Methotrexate—breast cancer	6.07e-05	0.000247	CcSEcCtD
Tapentadol—Hypersensitivity—Capecitabine—breast cancer	6.05e-05	0.000246	CcSEcCtD
Tapentadol—Pruritus—Docetaxel—breast cancer	6e-05	0.000244	CcSEcCtD
Tapentadol—Nervous system disorder—Methotrexate—breast cancer	5.99e-05	0.000244	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—breast cancer	5.97e-05	0.000243	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—breast cancer	5.96e-05	0.000243	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—breast cancer	5.95e-05	0.000242	CcSEcCtD
Tapentadol—Nausea—Paclitaxel—breast cancer	5.94e-05	0.000242	CcSEcCtD
Tapentadol—Skin disorder—Methotrexate—breast cancer	5.94e-05	0.000242	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.93e-05	0.000241	CcSEcCtD
Tapentadol—Hyperhidrosis—Methotrexate—breast cancer	5.91e-05	0.00024	CcSEcCtD
Tapentadol—Asthenia—Capecitabine—breast cancer	5.89e-05	0.00024	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—breast cancer	5.84e-05	0.000238	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—breast cancer	5.83e-05	0.000237	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—breast cancer	5.82e-05	0.000237	CcSEcCtD
Tapentadol—Pruritus—Capecitabine—breast cancer	5.81e-05	0.000236	CcSEcCtD
Tapentadol—Diarrhoea—Docetaxel—breast cancer	5.8e-05	0.000236	CcSEcCtD
Tapentadol—Confusional state—Epirubicin—breast cancer	5.77e-05	0.000235	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—breast cancer	5.73e-05	0.000233	CcSEcCtD
Tapentadol—Anaphylactic shock—Epirubicin—breast cancer	5.72e-05	0.000233	CcSEcCtD
Tapentadol—Oedema—Epirubicin—breast cancer	5.72e-05	0.000233	CcSEcCtD
Tapentadol—Hypotension—Methotrexate—breast cancer	5.71e-05	0.000232	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—breast cancer	5.7e-05	0.000232	CcSEcCtD
Tapentadol—Infection—Epirubicin—breast cancer	5.68e-05	0.000231	CcSEcCtD
Tapentadol—Cough—Doxorubicin—breast cancer	5.66e-05	0.00023	CcSEcCtD
Tapentadol—Shock—Epirubicin—breast cancer	5.63e-05	0.000229	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—breast cancer	5.62e-05	0.000229	CcSEcCtD
Tapentadol—Diarrhoea—Capecitabine—breast cancer	5.62e-05	0.000229	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—breast cancer	5.61e-05	0.000228	CcSEcCtD
Tapentadol—Dizziness—Docetaxel—breast cancer	5.61e-05	0.000228	CcSEcCtD
Tapentadol—Tachycardia—Epirubicin—breast cancer	5.58e-05	0.000227	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Methotrexate—breast cancer	5.57e-05	0.000227	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—breast cancer	5.56e-05	0.000226	CcSEcCtD
Tapentadol—Hyperhidrosis—Epirubicin—breast cancer	5.53e-05	0.000225	CcSEcCtD
Tapentadol—Insomnia—Methotrexate—breast cancer	5.53e-05	0.000225	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—breast cancer	5.52e-05	0.000225	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—breast cancer	5.5e-05	0.000224	CcSEcCtD
Tapentadol—Paraesthesia—Methotrexate—breast cancer	5.49e-05	0.000223	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5.48e-05	0.000223	CcSEcCtD
Tapentadol—Dyspnoea—Methotrexate—breast cancer	5.45e-05	0.000222	CcSEcCtD
Tapentadol—Somnolence—Methotrexate—breast cancer	5.43e-05	0.000221	CcSEcCtD
Tapentadol—Dizziness—Capecitabine—breast cancer	5.43e-05	0.000221	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—breast cancer	5.4e-05	0.00022	CcSEcCtD
Tapentadol—Vomiting—Docetaxel—breast cancer	5.39e-05	0.000219	CcSEcCtD
Tapentadol—Dyspepsia—Methotrexate—breast cancer	5.38e-05	0.000219	CcSEcCtD
Tapentadol—Rash—Docetaxel—breast cancer	5.35e-05	0.000218	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—breast cancer	5.34e-05	0.000218	CcSEcCtD
Tapentadol—Dermatitis—Docetaxel—breast cancer	5.34e-05	0.000217	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—breast cancer	5.34e-05	0.000217	CcSEcCtD
Tapentadol—Decreased appetite—Methotrexate—breast cancer	5.31e-05	0.000216	CcSEcCtD
Tapentadol—Headache—Docetaxel—breast cancer	5.31e-05	0.000216	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—breast cancer	5.29e-05	0.000215	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—breast cancer	5.29e-05	0.000215	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Methotrexate—breast cancer	5.28e-05	0.000215	CcSEcCtD
Tapentadol—Fatigue—Methotrexate—breast cancer	5.27e-05	0.000214	CcSEcCtD
Tapentadol—Infection—Doxorubicin—breast cancer	5.26e-05	0.000214	CcSEcCtD
Tapentadol—Vomiting—Capecitabine—breast cancer	5.22e-05	0.000212	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—breast cancer	5.21e-05	0.000212	CcSEcCtD
Tapentadol—Shock—Doxorubicin—breast cancer	5.21e-05	0.000212	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—breast cancer	5.19e-05	0.000211	CcSEcCtD
Tapentadol—Rash—Capecitabine—breast cancer	5.18e-05	0.000211	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—breast cancer	5.17e-05	0.000211	CcSEcCtD
Tapentadol—Dermatitis—Capecitabine—breast cancer	5.17e-05	0.000211	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—breast cancer	5.17e-05	0.00021	CcSEcCtD
Tapentadol—Headache—Capecitabine—breast cancer	5.14e-05	0.000209	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—breast cancer	5.14e-05	0.000209	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—breast cancer	5.14e-05	0.000209	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—breast cancer	5.12e-05	0.000208	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—breast cancer	5.1e-05	0.000208	CcSEcCtD
Tapentadol—Somnolence—Epirubicin—breast cancer	5.09e-05	0.000207	CcSEcCtD
Tapentadol—Nausea—Docetaxel—breast cancer	5.04e-05	0.000205	CcSEcCtD
Tapentadol—Feeling abnormal—Methotrexate—breast cancer	5.04e-05	0.000205	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—breast cancer	5.04e-05	0.000205	CcSEcCtD
Tapentadol—Decreased appetite—Epirubicin—breast cancer	4.97e-05	0.000202	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—breast cancer	4.95e-05	0.000201	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—breast cancer	4.94e-05	0.000201	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—breast cancer	4.93e-05	0.000201	CcSEcCtD
Tapentadol—Constipation—Epirubicin—breast cancer	4.89e-05	0.000199	CcSEcCtD
Tapentadol—Nausea—Capecitabine—breast cancer	4.88e-05	0.000198	CcSEcCtD
Tapentadol—Urticaria—Methotrexate—breast cancer	4.86e-05	0.000198	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.82e-05	0.000196	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—breast cancer	4.79e-05	0.000195	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—breast cancer	4.75e-05	0.000193	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—breast cancer	4.72e-05	0.000192	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—breast cancer	4.71e-05	0.000192	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—breast cancer	4.71e-05	0.000191	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—breast cancer	4.66e-05	0.00019	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—breast cancer	4.6e-05	0.000187	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—breast cancer	4.57e-05	0.000186	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—breast cancer	4.56e-05	0.000186	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—breast cancer	4.54e-05	0.000185	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—breast cancer	4.53e-05	0.000184	CcSEcCtD
Tapentadol—Hypersensitivity—Methotrexate—breast cancer	4.5e-05	0.000183	CcSEcCtD
Tapentadol—Asthenia—Methotrexate—breast cancer	4.39e-05	0.000178	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—breast cancer	4.36e-05	0.000178	CcSEcCtD
Tapentadol—Pruritus—Methotrexate—breast cancer	4.32e-05	0.000176	CcSEcCtD
Tapentadol—Hypersensitivity—Epirubicin—breast cancer	4.21e-05	0.000172	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—breast cancer	4.2e-05	0.000171	CcSEcCtD
Tapentadol—Diarrhoea—Methotrexate—breast cancer	4.18e-05	0.00017	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—breast cancer	4.1e-05	0.000167	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—breast cancer	4.05e-05	0.000165	CcSEcCtD
Tapentadol—Dizziness—Methotrexate—breast cancer	4.04e-05	0.000164	CcSEcCtD
Tapentadol—Diarrhoea—Epirubicin—breast cancer	3.91e-05	0.000159	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—breast cancer	3.9e-05	0.000159	CcSEcCtD
Tapentadol—Vomiting—Methotrexate—breast cancer	3.89e-05	0.000158	CcSEcCtD
Tapentadol—Rash—Methotrexate—breast cancer	3.85e-05	0.000157	CcSEcCtD
Tapentadol—Dermatitis—Methotrexate—breast cancer	3.85e-05	0.000157	CcSEcCtD
Tapentadol—Headache—Methotrexate—breast cancer	3.83e-05	0.000156	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—breast cancer	3.8e-05	0.000155	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—breast cancer	3.78e-05	0.000154	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—breast cancer	3.74e-05	0.000152	CcSEcCtD
Tapentadol—Vomiting—Epirubicin—breast cancer	3.64e-05	0.000148	CcSEcCtD
Tapentadol—Nausea—Methotrexate—breast cancer	3.63e-05	0.000148	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—breast cancer	3.62e-05	0.000147	CcSEcCtD
Tapentadol—Rash—Epirubicin—breast cancer	3.61e-05	0.000147	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—breast cancer	3.6e-05	0.000147	CcSEcCtD
Tapentadol—Headache—Epirubicin—breast cancer	3.58e-05	0.000146	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—breast cancer	3.5e-05	0.000142	CcSEcCtD
Tapentadol—Nausea—Epirubicin—breast cancer	3.4e-05	0.000138	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—breast cancer	3.37e-05	0.000137	CcSEcCtD
Tapentadol—Rash—Doxorubicin—breast cancer	3.34e-05	0.000136	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—breast cancer	3.33e-05	0.000136	CcSEcCtD
Tapentadol—Headache—Doxorubicin—breast cancer	3.32e-05	0.000135	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—breast cancer	3.14e-05	0.000128	CcSEcCtD
Tapentadol—CYP2C9—Metabolism—CYP17A1—breast cancer	5.98e-06	4.19e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB2—breast cancer	5.97e-06	4.19e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ENO1—breast cancer	5.97e-06	4.19e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS1—breast cancer	5.97e-06	4.19e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC5A5—breast cancer	5.96e-06	4.18e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FN1—breast cancer	5.96e-06	4.18e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CD—breast cancer	5.93e-06	4.16e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ENO1—breast cancer	5.92e-06	4.15e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS1—breast cancer	5.92e-06	4.15e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	5.9e-06	4.13e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MTOR—breast cancer	5.89e-06	4.13e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CB—breast cancer	5.89e-06	4.13e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NFKBIA—breast cancer	5.89e-06	4.13e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—breast cancer	5.87e-06	4.12e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SERPINE1—breast cancer	5.86e-06	4.11e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOTCH1—breast cancer	5.83e-06	4.09e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	5.82e-06	4.08e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—breast cancer	5.8e-06	4.07e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2D6—breast cancer	5.8e-06	4.07e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NOS3—breast cancer	5.79e-06	4.06e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC2A1—breast cancer	5.76e-06	4.04e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NQO1—breast cancer	5.76e-06	4.04e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NCOA2—breast cancer	5.75e-06	4.03e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CG—breast cancer	5.7e-06	4e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KIT—breast cancer	5.7e-06	4e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APC—breast cancer	5.7e-06	4e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NCOA2—breast cancer	5.7e-06	3.99e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—breast cancer	5.68e-06	3.98e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL8—breast cancer	5.66e-06	3.97e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	5.64e-06	3.95e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGF—breast cancer	5.63e-06	3.95e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—breast cancer	5.63e-06	3.94e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP3A4—breast cancer	5.61e-06	3.94e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOS3—breast cancer	5.6e-06	3.93e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	5.59e-06	3.92e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—FASN—breast cancer	5.57e-06	3.91e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—BCHE—breast cancer	5.55e-06	3.89e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1B—breast cancer	5.53e-06	3.88e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—FASN—breast cancer	5.53e-06	3.87e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1B1—breast cancer	5.52e-06	3.87e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—BCHE—breast cancer	5.5e-06	3.86e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC5A5—breast cancer	5.48e-06	3.84e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—breast cancer	5.47e-06	3.84e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK3—breast cancer	5.46e-06	3.83e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC5A5—breast cancer	5.44e-06	3.81e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—breast cancer	5.42e-06	3.8e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HSP90AA1—breast cancer	5.41e-06	3.79e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—breast cancer	5.41e-06	3.79e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—breast cancer	5.39e-06	3.78e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BRAF—breast cancer	5.36e-06	3.76e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CB—breast cancer	5.34e-06	3.75e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—breast cancer	5.33e-06	3.74e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MDM2—breast cancer	5.31e-06	3.72e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC2A1—breast cancer	5.3e-06	3.71e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NQO1—breast cancer	5.3e-06	3.71e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RAF1—breast cancer	5.29e-06	3.71e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—breast cancer	5.29e-06	3.71e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—breast cancer	5.28e-06	3.7e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RELA—breast cancer	5.27e-06	3.69e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NCOA1—breast cancer	5.27e-06	3.69e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JUN—breast cancer	5.27e-06	3.69e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NQO1—breast cancer	5.25e-06	3.68e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC2A1—breast cancer	5.25e-06	3.68e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB2—breast cancer	5.24e-06	3.67e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CTNNB1—breast cancer	5.23e-06	3.66e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1—breast cancer	5.22e-06	3.66e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT2—breast cancer	5.22e-06	3.66e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—breast cancer	5.19e-06	3.64e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—STK11—breast cancer	5.19e-06	3.64e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP19A1—breast cancer	5.19e-06	3.64e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CB—breast cancer	5.17e-06	3.62e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MTOR—breast cancer	5.17e-06	3.62e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP3A4—breast cancer	5.16e-06	3.62e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	5.14e-06	3.6e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—breast cancer	5.12e-06	3.59e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP3A4—breast cancer	5.12e-06	3.59e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1A—breast cancer	5.1e-06	3.58e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	5.09e-06	3.57e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—breast cancer	5.09e-06	3.57e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1B1—breast cancer	5.08e-06	3.56e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1B1—breast cancer	5.03e-06	3.53e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CD—breast cancer	5.01e-06	3.51e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK8—breast cancer	4.98e-06	3.49e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HSP90AA1—breast cancer	4.98e-06	3.49e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—breast cancer	4.97e-06	3.48e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL8—breast cancer	4.97e-06	3.48e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—breast cancer	4.96e-06	3.48e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SERPINE1—breast cancer	4.96e-06	3.47e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HSP90AA1—breast cancer	4.94e-06	3.46e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—breast cancer	4.93e-06	3.46e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—breast cancer	4.91e-06	3.44e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—breast cancer	4.87e-06	3.42e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1B—breast cancer	4.85e-06	3.4e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NCOA1—breast cancer	4.84e-06	3.4e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—COMT—breast cancer	4.82e-06	3.38e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—breast cancer	4.8e-06	3.37e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NCOA1—breast cancer	4.8e-06	3.37e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—breast cancer	4.8e-06	3.36e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—STK11—breast cancer	4.77e-06	3.35e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP19A1—breast cancer	4.77e-06	3.35e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—breast cancer	4.75e-06	3.33e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—breast cancer	4.75e-06	3.33e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HMOX1—breast cancer	4.74e-06	3.32e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP19A1—breast cancer	4.73e-06	3.32e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—STK11—breast cancer	4.73e-06	3.32e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOS3—breast cancer	4.73e-06	3.32e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ITPR1—breast cancer	4.72e-06	3.31e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SRC—breast cancer	4.72e-06	3.31e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—breast cancer	4.72e-06	3.31e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—breast cancer	4.63e-06	3.24e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUN—breast cancer	4.62e-06	3.24e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—breast cancer	4.62e-06	3.24e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—breast cancer	4.6e-06	3.22e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CTNNB1—breast cancer	4.58e-06	3.21e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—breast cancer	4.55e-06	3.19e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCB1—breast cancer	4.55e-06	3.19e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—breast cancer	4.51e-06	3.16e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—breast cancer	4.49e-06	3.15e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MDM2—breast cancer	4.49e-06	3.15e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1A—breast cancer	4.48e-06	3.14e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RAF1—breast cancer	4.47e-06	3.14e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—breast cancer	4.47e-06	3.13e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TYMS—breast cancer	4.46e-06	3.13e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RELA—breast cancer	4.45e-06	3.12e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	4.44e-06	3.11e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—COMT—breast cancer	4.44e-06	3.11e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB2—breast cancer	4.43e-06	3.1e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—breast cancer	4.42e-06	3.1e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PLA2G4A—breast cancer	4.41e-06	3.09e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NCOR1—breast cancer	4.41e-06	3.09e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—breast cancer	4.41e-06	3.09e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—COMT—breast cancer	4.4e-06	3.08e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—breast cancer	4.38e-06	3.07e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK8—breast cancer	4.37e-06	3.06e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MTOR—breast cancer	4.37e-06	3.06e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CB—breast cancer	4.37e-06	3.06e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—breast cancer	4.36e-06	3.05e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HMOX1—breast cancer	4.36e-06	3.05e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK3—breast cancer	4.35e-06	3.05e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ITPR1—breast cancer	4.35e-06	3.05e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HMOX1—breast cancer	4.32e-06	3.03e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ITPR1—breast cancer	4.31e-06	3.02e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—breast cancer	4.23e-06	2.97e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPX1—breast cancer	4.23e-06	2.96e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFB1—breast cancer	4.22e-06	2.96e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL8—breast cancer	4.2e-06	2.94e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1A1—breast cancer	4.18e-06	2.93e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCB1—breast cancer	4.18e-06	2.93e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—breast cancer	4.17e-06	2.92e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ERCC2—breast cancer	4.15e-06	2.91e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCB1—breast cancer	4.14e-06	2.91e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SRC—breast cancer	4.14e-06	2.9e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—breast cancer	4.14e-06	2.9e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TYMS—breast cancer	4.11e-06	2.88e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1B—breast cancer	4.1e-06	2.87e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TYMS—breast cancer	4.07e-06	2.85e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—breast cancer	4.06e-06	2.85e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PLA2G4A—breast cancer	4.06e-06	2.85e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NCOR1—breast cancer	4.06e-06	2.85e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—breast cancer	4.05e-06	2.84e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—breast cancer	4.03e-06	2.83e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NCOR1—breast cancer	4.02e-06	2.82e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PLA2G4A—breast cancer	4.02e-06	2.82e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—breast cancer	4.02e-06	2.82e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—breast cancer	4.02e-06	2.82e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—breast cancer	4.01e-06	2.81e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—breast cancer	4.01e-06	2.81e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—breast cancer	3.99e-06	2.8e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—breast cancer	3.99e-06	2.8e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—breast cancer	3.91e-06	2.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—breast cancer	3.91e-06	2.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUN—breast cancer	3.9e-06	2.74e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MTHFR—breast cancer	3.9e-06	2.73e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPX1—breast cancer	3.89e-06	2.72e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CTNNB1—breast cancer	3.87e-06	2.71e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPX1—breast cancer	3.85e-06	2.7e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1A1—breast cancer	3.85e-06	2.7e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ERCC2—breast cancer	3.82e-06	2.68e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK3—breast cancer	3.82e-06	2.68e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1A1—breast cancer	3.81e-06	2.67e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—breast cancer	3.8e-06	2.66e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ERCC2—breast cancer	3.78e-06	2.65e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1A—breast cancer	3.78e-06	2.65e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—breast cancer	3.77e-06	2.65e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—breast cancer	3.71e-06	2.6e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFB1—breast cancer	3.7e-06	2.6e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK8—breast cancer	3.69e-06	2.59e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—breast cancer	3.68e-06	2.58e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—breast cancer	3.63e-06	2.54e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CAV1—breast cancer	3.6e-06	2.52e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—breast cancer	3.59e-06	2.52e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTHFR—breast cancer	3.59e-06	2.51e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTHFR—breast cancer	3.56e-06	2.49e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SRC—breast cancer	3.5e-06	2.45e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—breast cancer	3.48e-06	2.44e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.44e-06	2.41e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—breast cancer	3.43e-06	2.4e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—breast cancer	3.41e-06	2.39e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—breast cancer	3.38e-06	2.37e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—breast cancer	3.32e-06	2.33e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CAV1—breast cancer	3.31e-06	2.32e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CAV1—breast cancer	3.28e-06	2.3e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CG—breast cancer	3.28e-06	2.3e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—breast cancer	3.27e-06	2.3e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—breast cancer	3.26e-06	2.28e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK3—breast cancer	3.22e-06	2.26e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—breast cancer	3.18e-06	2.23e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—breast cancer	3.15e-06	2.21e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—breast cancer	3.14e-06	2.2e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.13e-06	2.2e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFB1—breast cancer	3.13e-06	2.19e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—breast cancer	3.07e-06	2.15e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—breast cancer	3.05e-06	2.14e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CG—breast cancer	3.01e-06	2.11e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CG—breast cancer	2.99e-06	2.09e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—breast cancer	2.93e-06	2.06e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—breast cancer	2.91e-06	2.04e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—breast cancer	2.9e-06	2.03e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CD—breast cancer	2.88e-06	2.02e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—breast cancer	2.84e-06	1.99e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—breast cancer	2.79e-06	1.96e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NOS3—breast cancer	2.72e-06	1.91e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—breast cancer	2.66e-06	1.87e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—breast cancer	2.66e-06	1.87e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CD—breast cancer	2.65e-06	1.86e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CD—breast cancer	2.63e-06	1.84e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—breast cancer	2.62e-06	1.83e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—breast cancer	2.59e-06	1.82e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—breast cancer	2.58e-06	1.81e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—breast cancer	2.57e-06	1.8e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CB—breast cancer	2.51e-06	1.76e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NOS3—breast cancer	2.5e-06	1.75e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—breast cancer	2.49e-06	1.74e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NOS3—breast cancer	2.48e-06	1.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—breast cancer	2.46e-06	1.73e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—breast cancer	2.36e-06	1.65e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CB—breast cancer	2.31e-06	1.62e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CB—breast cancer	2.29e-06	1.6e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—breast cancer	2.29e-06	1.6e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—breast cancer	2.27e-06	1.59e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—breast cancer	2.18e-06	1.52e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—breast cancer	2.17e-06	1.52e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—breast cancer	2e-06	1.4e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—breast cancer	1.98e-06	1.39e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—breast cancer	1.53e-06	1.07e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—breast cancer	1.41e-06	9.87e-06	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—breast cancer	1.4e-06	9.78e-06	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—breast cancer	1.25e-06	8.77e-06	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—breast cancer	1.15e-06	8.06e-06	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—breast cancer	1.14e-06	7.99e-06	CbGpPWpGaD
